![](/img/cover-not-exists.png)
Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
Lee, C-H., Adachi, Y., Ikezawa, H., Li, S.D., Funahashi, Y., Minoshima, Y., Kubiak, P., Perini, R., Ren, M., Smith, A.D., Motzer, R.J.Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.791
Date:
September, 2020
File:
PDF, 101 KB
2020